Show simple item record

dc.contributor.authorMillward, CP
dc.contributor.authorArmstrong, TS
dc.contributor.authorBarrington, H
dc.contributor.authorBell, S
dc.contributor.authorBrodbelt, AR
dc.contributor.authorBulbeck, H
dc.contributor.authorCrofton, A
dc.contributor.authorDirven, L
dc.contributor.authorGeorgious, T
dc.contributor.authorGrundy, PL
dc.contributor.authorIslim, AI
dc.contributor.authorJavadpour, M
dc.contributor.authorKeshwara, SM
dc.contributor.authorKoszdin, SD
dc.contributor.authorMarson, AG
dc.contributor.authorMcDermott, MW
dc.contributor.authorMeling, TR
dc.contributor.authorOliver, K
dc.contributor.authorPlaha, P
dc.contributor.authorPreusser, M
dc.contributor.authorSantarius, T
dc.contributor.authorSrikandarajah, N
dc.contributor.authorTaphoorn, MJB
dc.contributor.authorTurner, C
dc.contributor.authorWatts, C
dc.contributor.authorWeller, M
dc.contributor.authorWilliamson, PR
dc.contributor.authorZadeh, G
dc.contributor.authorZamanipoor Najafabadi, AH
dc.contributor.authorJenkinson, MD
dc.date.accessioned2022-07-01T14:26:47Z
dc.date.available2022-07-01T14:26:47Z
dc.date.issued2022-05-09
dc.identifier.issn2044-6055
dc.identifier.issn2044-6055
dc.identifier.othere057384
dc.identifier.urihttp://hdl.handle.net/10026.1/19375
dc.description.abstract

<jats:sec><jats:title>Introduction</jats:title><jats:p>Meningioma is the most common primary intracranial tumour in adults. The majority are non-malignant, but a proportion behave more aggressively. Incidental/minimally symptomatic meningioma are often managed by serial imaging. Symptomatic meningioma, those that threaten neurovascular structures, or demonstrate radiological growth, are usually resected as first-line management strategy. For patients in poor clinical condition, or with inoperable, residual or recurrent disease, radiotherapy is often used as primary or adjuvant treatment. Effective pharmacotherapy treatments do not currently exist. There is heterogeneity in the outcomes measured and reported in meningioma clinical studies. Two ‘Core Outcome Sets’ (COS) will be developed: (COSMIC: Intervention) for use in meningioma clinical effectiveness trials and (COSMIC: Observation) for use in clinical studies of incidental/untreated meningioma.</jats:p></jats:sec><jats:sec><jats:title>Methods and analysis</jats:title><jats:p>Two systematic literature reviews and trial registry searches will identify outcomes measured and reported in published and ongoing (1) meningioma clinical effectiveness trials, and (2) clinical studies of incidental/untreated meningioma. Outcomes include those that are clinician reported, patient reported, caregiver reported and based on objective tests (eg, neurocognitive tests), as well as measures of progression and survival. Outcomes will be deduplicated and categorised to generate two long lists. The two long lists will be prioritised through two, two-round, international, modified eDelphi surveys including patients with meningioma, healthcare professionals, researchers and those in caring/supporting roles. The two final COS will be ratified through two 1-day online consensus meetings, with representation from all stakeholder groups.</jats:p></jats:sec><jats:sec><jats:title>Ethics and dissemination</jats:title><jats:p>Institutional review board (University of Liverpool) approval was obtained for the conduct of this study. Participant eConsent will be obtained prior to participation in the eDelphi surveys and consensus meetings. The two systematic literature reviews and two final COS will be published and freely available.</jats:p></jats:sec><jats:sec><jats:title>Trial registration number</jats:title><jats:p>COMET study ID 1508</jats:p></jats:sec>

dc.format.extente057384-e057384
dc.format.mediumElectronic
dc.languageen
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.subjectclinical trial
dc.subjectcore outcome set
dc.subjectmeningioma
dc.subjectConsensus
dc.subjectDelphi Technique
dc.subjectHumans
dc.subjectMeningeal Neoplasms
dc.subjectMeningioma
dc.subjectResearch Design
dc.subjectSystematic Reviews as Topic
dc.subjectTreatment Outcome
dc.titleDevelopment of ‘Core Outcome Sets’ for Meningioma in Clinical Studies (The COSMIC Project): protocol for two systematic literature reviews, eDelphi surveys and online consensus meetings
dc.typejournal-article
dc.typeJournal Article
dc.typeResearch Support, Non-U.S. Gov't
plymouth.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/35534067
plymouth.issue5
plymouth.volume12
plymouth.publication-statusPublished
plymouth.journalBMJ Open
dc.identifier.doi10.1136/bmjopen-2021-057384
plymouth.organisational-group/Plymouth
plymouth.organisational-group/Plymouth/Faculty of Health
plymouth.organisational-group/Plymouth/Faculty of Health/Peninsula Medical School
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA
plymouth.organisational-group/Plymouth/REF 2021 Researchers by UoA/UoA01 Clinical Medicine
plymouth.organisational-group/Plymouth/Research Groups
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)
plymouth.organisational-group/Plymouth/Research Groups/Institute of Translational and Stratified Medicine (ITSMED)/CBR
plymouth.organisational-group/Plymouth/Users by role
plymouth.organisational-group/Plymouth/Users by role/Academics
plymouth.organisational-group/Plymouth/Users by role/Researchers in ResearchFish submission
dc.publisher.placeEngland
dcterms.dateAccepted2022-04-07
dc.rights.embargodate2022-7-2
dc.identifier.eissn2044-6055
dc.rights.embargoperiodNot known
rioxxterms.versionofrecord10.1136/bmjopen-2021-057384
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.typeJournal Article/Review


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record


All items in PEARL are protected by copyright law.
Author manuscripts deposited to comply with open access mandates are made available in accordance with publisher policies. Please cite only the published version using the details provided on the item record or document. In the absence of an open licence (e.g. Creative Commons), permissions for further reuse of content should be sought from the publisher or author.
Theme by 
Atmire NV